Compare NICE Ltd (NICE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Sana Biotechnology Inc — how do they compare? NICE Ltd trades at $98.25 (market cap $6.02B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: NICE Ltd is far larger — about 5.3× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| NICE | SANA | |
|---|---|---|
Market Cap | $6.02B | $1.13B |
Sector | Technology | Health |
52-Week High | $153.44 | $5.92 |
52-Week Low | $83.15 | $2.68 |
Enterprise Value | $5.75B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $98.71, down 3.76% today, but maintains a bullish technical outlook with support near $99. The company reported Q2 2026 earnings beats, with revenue growth of 7.6% year-over-year to $782.3 million (Business Wire, 2026-08-05). Valuation metrics appear reasonable with a P/E of 14.8 and P/S of 2.03. Recent news highlights partnerships with Currys and RingCentral to enhance AI-driven customer engagement.
The investment outlook is positive, supported by strong analyst consensus with a $115 price target (52% buy ratings). Key opportunities include cloud and AI growth, while risks involve execution challenges and potential margin pressure from increased investments. The stock offers ~16.5% upside to the consensus target, but investors should monitor Q3 2026 earnings due to expected EPS of 2.76.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
